Clinical Trials Logo

Clinical Trial Summary

The goal of this observational study is to study the genetic landscape in patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis in Thailand. The main questions it aims to answer are: - genetic landscape in patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis in Thailand who were performed FISH and/or NGS testing - genetic correlation and genetic dependency between FISH and NGS, stratified by high- and standard-risk groups based on FISH testing in Thai MM patients. - disease characteristics and response rates in MM patients with cytogenetic abnormalities detected by FISH and/or genetic mutations detected by NGS. - correlation between cytogenetic abnormalities identified by FISH and genetic mutations detected by NGS with progression-free survival in MM patients. The FISH and/or NGS testing results, disease characteristics, treatment, and treatment outcomes of patients with plasma cell disorders who underwent FISH and/or NGS testing before IRB approval will be collected through retrospective chart review. Subsequently, data will be gathered prospectively. Participants will provide approximately 12 mL of bone marrow fluid for FISH and NGS testing.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06330896
Study type Observational
Source Siriraj Hospital
Contact Chutima Kunacheewa
Phone 66896790959
Email chutima.kua@mahidol.ac.th
Status Not yet recruiting
Phase
Start date April 1, 2024
Completion date April 1, 2028

See also
  Status Clinical Trial Phase
Completed NCT05032339 - Evaluation of the Plasma Cell Disorders Panel on the BD FACSLyric™ Flow Cytometer
Active, not recruiting NCT03480360 - Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Phase 3
Not yet recruiting NCT06313502 - High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders Phase 1
Recruiting NCT04879043 - Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma Phase 1/Phase 2
Completed NCT02274519 - Novel Support Options in Autologous Stem Cell Transplant for Multiple Myeloma N/A
Active, not recruiting NCT02041325 - Investigation of the Enhancement of the Response to Hepatitis B Vaccine by Lenalidomide (RevlimidTM, CC-5013) in Plasma Cell Dyscrasias Phase 2